论文部分内容阅读
目的:观察复方血栓通胶囊治疗急性中心性浆液性脉络膜视网膜病变(CSC)的临床疗效和安全性。方法:急性CSC患者83例(83眼)随机分为观察组42例(42眼)和对照组41例(41眼)。对照组给予口服维生素E软胶囊0.1g,qd,维生素C片0.2g,tid,维生素B1片10mg,tid;,观察组在对照组治疗基础上加用复方血栓通胶囊1.5g,po,tid。持续服用2个月,比较两组临床疗效、治愈时间、视力恢复时间、药品不良反应以及治疗前后视力、光学相干断层扫描技术(OCT)检查结果变化;随访3个月,比较两组复发率。结果:观察组总有效率为90.5%,显著高于对照组的26.8%(P<0.05)。观察组治疗1,4,8周后视力均明显优于对照组(P<0.05),治愈时间、视力恢复时间也显著短于对照组(P<0.05)。治疗后,两组黄斑中心区直径1mm范围的厚度、黄斑中心区直径6mm的平均厚度和黄斑中心区直径6mm的总体积均较治疗前显著降低(P<0.05),且观察组明显低于对照组(P<0.05)。随访3个月,观察组复发率明显低于对照组(P<0.05)。两组患者均未发生药品不良反应。结论:复方血栓通胶囊治疗急性CSC能显著提高疗效,且安全性较好。
Objective: To observe the clinical efficacy and safety of compound Xueshuantong capsule in the treatment of acute central serous chorioretinopathy (CSC). Methods: 83 patients (83 eyes) with acute CSC were randomly divided into observation group (42 eyes) and control group (41 eyes). The control group was given oral vitamin E soft capsule 0.1g, qd, vitamin C tablets 0.2g, tid, vitamin B1 tablets 10mg, tid ;, observation group in the control group based on the use of compound Xueshuantong capsule 1.5g, po, tid. The patients were followed up for 2 months. The clinical curative effect, cure time, visual acuity recovery time, adverse drug reaction and visual acuity and optical coherence tomography (OCT) before and after treatment were compared. The follow-up was 3 months. The recurrence rate was compared between the two groups. Results: The total effective rate in observation group was 90.5%, significantly higher than that in control group (26.8%, P <0.05). Visual acuity in the observation group was significantly better than that in the control group (P <0.05) after 1, 4 and 8 weeks of treatment. The healing time and visual recovery time were also significantly shorter in the observation group than those in the control group (P <0.05). After treatment, the thickness of the macula central area 1 mm in diameter, the average thickness of the macular central area 6 mm and the central macula 6 mm in diameter were significantly lower than those before treatment (P <0.05), and the observation group was significantly lower than the control Group (P <0.05). Follow-up for 3 months, the recurrence rate in the observation group was significantly lower than that in the control group (P <0.05). Two groups of patients did not occur adverse drug reactions. Conclusion: Compound Xueshuantong capsule can improve the curative effect of acute CSC, and its safety is better.